WILMINGTON, N.C., March 25 /PRNewswire-FirstCall/ --
aaiPharma Inc. (Nasdaq: AAII), a science-based specialty pharmaceutical
company, today announced the launch and first commercial sale of Calcitriol
Injection, a liquid, injectable vitamin D product used primarily to treat
chronic kidney dialysis patients with abnormally low levels of calcium in the
circulating blood, and the first line extension to its family of critical care
nutrition products.
On February 20, 2003, aaiPharma announced that the U.S. Food and Drug
Administration (FDA) had granted marketing approval for Calcitriol Injection.
With this approval, the FDA also granted the Company "shared market
exclusivity." According to the terms of the shared exclusivity, the 180-day
exclusivity time period starts upon the first commercial sale of Calcitriol by
either of the companies sharing exclusivity. aaiPharma believes that, with
its launch, it is the first company of the two companies to enter the market.
"We are very pleased to make our Calcitriol Injection product, packaged in
a unique vial format, commercially available," said Dr. Philip Tabbiner,
President and Chief Executive Officer of aaiPharma. "This launch is an
exciting milestone for aaiPharma."
About aaiPharma
aaiPharma Inc. is a leading, science-based specialty pharmaceutical
company with corporate headquarters in Wilmington, North Carolina. With more
than 23 years of drug development expertise and a proven sales and marketing
track record, the Company is focused on acquiring, improving and marketing
well-known, branded medicines in pain management, gastroenterology and
critical care. In addition to its branded product portfolio and robust
pipeline, aaiPharma continues to offer comprehensive drug development services
to the pharmaceutical, biotechnology, generic and device industries through
its services division, AAI International. For more information, please visit
aaiPharma's website at http://www.aaipharma.com.
SOURCE aaiPharma Inc.
 back to top
Related links:
http://www.aaipharma.com
CONTACT:
media, Andrea L. Johnston, Vice President of
Corporate Communications, +1-910-254-7340, or investors, James B.
Sloan, Jr., Senior Vice President, Corporate Finance,
+1-910-254-7690, both of aaiPharma Inc.
|
